NO20006604L - Fremgangsmåter og transdermale sammensetninger for lindring av smerte - Google Patents

Fremgangsmåter og transdermale sammensetninger for lindring av smerte

Info

Publication number
NO20006604L
NO20006604L NO20006604A NO20006604A NO20006604L NO 20006604 L NO20006604 L NO 20006604L NO 20006604 A NO20006604 A NO 20006604A NO 20006604 A NO20006604 A NO 20006604A NO 20006604 L NO20006604 L NO 20006604L
Authority
NO
Norway
Prior art keywords
methods
pain relief
transdermal compositions
compositions
amine
Prior art date
Application number
NO20006604A
Other languages
English (en)
Other versions
NO20006604D0 (no
Inventor
Robert W Murdock
C Donald Williams
Original Assignee
Pharmaceuticals Applic Associa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/106,684 external-priority patent/US6290986B1/en
Application filed by Pharmaceuticals Applic Associa filed Critical Pharmaceuticals Applic Associa
Publication of NO20006604D0 publication Critical patent/NO20006604D0/no
Publication of NO20006604L publication Critical patent/NO20006604L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet fremgangsmåter og sammensetninger for transdermal administrering. Det er beskrevet trekk omfattende fremgangsmåter og sammensetninger for transdermal administrering av en amininneholdende forbindelse med bifasisk oppløselighet og/eller et middel som forsterker aktiviteten av den amininneholdende forbindelsen som har bifasisk oppløselighet, for eksempel et muskelavslappende middel, for å lindre smerte.
NO20006604A 1998-06-29 2000-12-22 Fremgangsmåter og transdermale sammensetninger for lindring av smerte NO20006604L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/106,684 US6290986B1 (en) 1996-10-24 1998-06-29 Method and composition for transdermal administration of pharmacologic agents
US12290399P 1999-03-05 1999-03-05
PCT/US1999/014653 WO2000000120A1 (en) 1998-06-29 1999-06-29 Methods and transdermal compositions for pain relief

Publications (2)

Publication Number Publication Date
NO20006604D0 NO20006604D0 (no) 2000-12-22
NO20006604L true NO20006604L (no) 2001-02-28

Family

ID=26803907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006604A NO20006604L (no) 1998-06-29 2000-12-22 Fremgangsmåter og transdermale sammensetninger for lindring av smerte

Country Status (18)

Country Link
EP (1) EP1093348A4 (no)
JP (1) JP2002519310A (no)
KR (1) KR20010078754A (no)
CN (1) CN1331576A (no)
AU (1) AU4841599A (no)
BG (1) BG105175A (no)
BR (1) BR9912508A (no)
CA (1) CA2335837A1 (no)
HR (1) HRP20000905A2 (no)
HU (1) HUP0102728A3 (no)
ID (1) ID28213A (no)
IL (1) IL140420A0 (no)
MX (1) MXPA00012767A (no)
NO (1) NO20006604L (no)
PL (1) PL345216A1 (no)
SK (1) SK20012000A3 (no)
TR (1) TR200003801T2 (no)
WO (1) WO2000000120A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572880B2 (en) * 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ATE289295T1 (de) 1997-04-22 2005-03-15 Euro Celtique Sa Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker
ATE305788T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
AU1261501A (en) * 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
IN191512B (no) * 2000-01-21 2003-12-06 Panacea Biotech
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
NZ524252A (en) * 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
DE10042412B4 (de) * 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
JP2005154368A (ja) * 2003-11-27 2005-06-16 Teikoku Seiyaku Co Ltd ジソピラミド含有神経因性疼痛の鎮痛剤
JP4807721B2 (ja) * 2004-01-29 2011-11-02 株式会社 メドレックス 消炎鎮痛外用剤
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
KR100880748B1 (ko) * 2006-08-29 2009-02-02 정헌택 디메톡시커큐민을 함유하는 혈관재협착 방지용 조성물
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010128807A2 (ko) * 2009-05-07 2010-11-11 (주)문엔제이 신경손상 및 신경질환 예방 또는 치료용 약학조성물
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US9446056B2 (en) * 2014-02-11 2016-09-20 Dr. Reddy's Laboratories Ltd. Parenteral compositions of celecoxib
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
AU2019365255B2 (en) 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
FR3108841B1 (fr) * 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395420A (en) * 1981-12-09 1983-07-26 Bernstein Joel E Method and composition for treating pruritis
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain

Also Published As

Publication number Publication date
WO2000000120A9 (en) 2000-03-30
CA2335837A1 (en) 2000-01-06
ID28213A (id) 2001-05-10
IL140420A0 (en) 2002-02-10
HUP0102728A2 (hu) 2002-03-28
EP1093348A1 (en) 2001-04-25
EP1093348A4 (en) 2003-07-16
BG105175A (bg) 2001-11-30
NO20006604D0 (no) 2000-12-22
SK20012000A3 (sk) 2001-08-06
HUP0102728A3 (en) 2002-12-28
AU4841599A (en) 2000-01-17
BR9912508A (pt) 2001-05-02
KR20010078754A (ko) 2001-08-21
MXPA00012767A (es) 2002-08-09
TR200003801T2 (tr) 2001-06-21
PL345216A1 (en) 2001-12-03
CN1331576A (zh) 2002-01-16
HRP20000905A2 (en) 2001-08-31
WO2000000120A1 (en) 2000-01-06
JP2002519310A (ja) 2002-07-02

Similar Documents

Publication Publication Date Title
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
TR200003801T2 (tr) Acı hafifletmek için deri üstü kompozisyonlar ve yöntemler
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DK1476141T3 (da) Manipulationssikrede anordninger til transdermal opioidadministration
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
PT998287E (pt) Utilizacao de levobupivacaina
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
DK0904067T3 (da) Transdermalt indgivet dextromethorpan som hostestillende middel
EP0754457A4 (en) ACTIVE AGAINST ADDICT
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
KR950016760A (ko) 치질 치료제
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application